Biosceptre is pleased to announce that an agreement has been signed with pre-clinical CAR T development company, Carina Biotech, that will see the advancement of a promising cancer immunotherapy.
Biosceptre, a biopharmaceutical company developing targeted therapeutics and immune-oncology products, has acquired the exclusive rights to Carina Biotech’s nfP2X7-targeted CAR-T cells and associated intellectual property, which has shown encouraging cancer-killing capacity against a number of cancers in pre-clinical testing.
Biosceptre and Carina will collaborate to further develop the nfP2X7 CAR-T program with the aim of advancing towards clinical trials in the near future. Under the terms of the deal Carina received an upfront cash payment and equity in Biosceptre.
“With this deal we are building on our commitment to therapies focussed on non-functional P2X7, a cancer target that has been shown to be present on the majority of cancers”, said Gavin Currie CEO of Biosceptre. “Our goal is to bring novel therapeutics to patients suffering from a wide range of malignancies and CAR-T therapy is an important part of our immune-oncology approach”.
Deborah Rathjen, PhD, CEO of Carina Biotech said
“This agreement with Biosceptre represents a significant milestone for Carina as it is the first commercial agreement involving our proprietary CAR-T technology. We believe that nfP2X7-targeting CAR-T cells hold significant promise as a potential treatment for a range of solid cancers and we are pleased to be working with Biosceptre to further bolster their pipeline of therapies exploiting the novel nfP2X7 target”.
“I would like to pay particular tribute to the Carina Board of Directors, led by our Chair Dr. Leanna Read, for their role in bringing this deal to fruition”, Dr Rathjen added.